SII gets approval for trial of children’s vaccine Novavax

Share this post on:

New Delhi, 28 September: The Central Government has given permission to the vaccine maker Serum Institute of India (SII) to test the vaccine in children of 7-11 years. America’s vaccine maker Novavax’s coronavirus vaccine will be tried on these children.

After detailed deliberations by a subject expert panel of the Central Drugs Standard Control Organization, the committee recommended the trial on children aged 7 to 11 years as per protocol.

It is worth mentioning that apart from SIIโ€™s Covishield, Novavax is also making a vaccine. Last month, SII CEO Adar Poonawalla said that he expects Novavax to be launched for public in October this year and for children in the first quarter of next year.

However, before SII, two vaccine manufacturing companies of India have started trials of corona vaccine on children. These include Bharat Biotech and Zydus Cadila. Serum has already started the trial of Covax on 12-17 year olds and it has shown good results.